BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 23319435)

  • 1. c-Kit expression as a prognostic molecular marker in patients with basal-like breast cancer.
    Kashiwagi S; Yashiro M; Takashima T; Aomatsu N; Kawajiri H; Ogawa Y; Onoda N; Ishikawa T; Wakasa K; Hirakawa K
    Br J Surg; 2013 Mar; 100(4):490-6. PubMed ID: 23319435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basal-like breast cancer defined by FOXC1 expression offers superior prognostic value: a retrospective immunohistochemical study.
    Ray PS; Bagaria SP; Wang J; Shamonki JM; Ye X; Sim MS; Steen S; Qu Y; Cui X; Giuliano AE
    Ann Surg Oncol; 2011 Dec; 18(13):3839-47. PubMed ID: 21424368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrotic focus in breast carcinomas: relationship with prognostic parameters and biomarkers.
    Mujtaba SS; Ni YB; Tsang JY; Chan SK; Yamaguchi R; Tanaka M; Tan PH; Tse GM
    Ann Surg Oncol; 2013 Sep; 20(9):2842-9. PubMed ID: 23539156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.
    Francis G; Beadle G; Thomas S; Mengersen K; Stein S
    Pathology; 2006 Oct; 38(5):391-8. PubMed ID: 17008275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.
    Nassar A; Sussman ZM; Lawson D; Cohen C
    Breast J; 2012 Sep; 18(5):399-405. PubMed ID: 22882580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors.
    Tawfik K; Kimler BF; Davis MK; Fan F; Tawfik O
    Hum Pathol; 2012 Jan; 43(1):23-30. PubMed ID: 21777944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P-cadherin and vimentin are useful basal markers in breast cancers.
    Tsang JY; Au SK; Ni YB; Shao MM; Siu WM; Hui SW; Chan SK; Chan KW; Kwok YK; Chan KF; Tse GM
    Hum Pathol; 2013 Dec; 44(12):2782-91. PubMed ID: 24139214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of basal-like subtype in triple-negative breast cancer.
    Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
    Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer.
    Sáez R; Molina MA; Ramsey EE; Rojo F; Keenan EJ; Albanell J; Lluch A; García-Conde J; Baselga J; Clinton GM
    Clin Cancer Res; 2006 Jan; 12(2):424-31. PubMed ID: 16428482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
    Wang Y; Yin Q; Yu Q; Zhang J; Liu Z; Wang S; Lv S; Niu Y
    Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Male breast cancer: immunohistochemical subtypes and clinical outcome characterization.
    Sánchez-Muñoz A; Román-Jobacho A; Pérez-Villa L; Sánchez-Rovira P; Miramón J; Pérez D; Sáez MI; de Luque V; Medina L; Ramírez-Tortosa CL; Vicioso L; Medina JA; Ribelles N; Alba E
    Oncology; 2012; 83(4):228-33. PubMed ID: 22907070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor grade and matrix metalloproteinase 2 expression in stromal fibroblasts help to stratify the high-risk group of patients with early breast cancer identified on the basis of st Gallen recommendations.
    Niemiec J; Adamczyk A; Małecki K; Ambicka A; Ryś J
    Clin Breast Cancer; 2013 Apr; 13(2):119-28. PubMed ID: 23375518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas.
    Ettl T; Schwarz S; Kleinsasser N; Hartmann A; Reichert TE; Driemel O
    Histopathology; 2008 Nov; 53(5):567-77. PubMed ID: 18983466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
    Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
    Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basal cytokeratin expression in relation to biological factors in breast cancer.
    Kuroda H; Ishida F; Nakai M; Ohnisi K; Itoyama S
    Hum Pathol; 2008 Dec; 39(12):1744-50. PubMed ID: 18755493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nerve growth factor receptor (NGFR): a potential marker for specific molecular subtypes of breast cancer.
    Tsang JY; Wong KH; Lai MW; Lacambra MD; Ko CW; Chan SK; Lam CC; Yu AM; Tan PH; Tse GM
    J Clin Pathol; 2013 Apr; 66(4):291-6. PubMed ID: 23268325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective analysis of risk factors for central nervous system metastases in operable breast cancer: effects of biologic subtype and Ki67 overexpression on survival.
    Ishihara M; Mukai H; Nagai S; Onozawa M; Nihei K; Shimada T; Wada N
    Oncology; 2013; 84(3):135-40. PubMed ID: 23235554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.